By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit, LinkedIn and follow us on


Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 20,000
Symbol: AMGN

Company News
Amgen (AMGN) Announces Voting Results Of Annual Meeting Of Stockholders 5/22/2017 9:39:55 AM
Amgen (AMGN) Release: Repatha (Evolocumab) Reduced Cardiovascular Events In Patients With Baseline LDL-C Levels Below Current Targets 5/22/2017 7:30:48 AM
Amgen (AMGN) Faces Setback as Osteoporosis Drug is Linked to Serious Heart Side Effects 5/21/2017 8:44:46 PM
Amgen (AMGN) Submits Biologics License Application To The FDA For Erenumab 5/18/2017 7:41:35 AM
These 2 Biotechs' Shark Antibodies Have Caught Amgen (AMGN)'s Eye 5/9/2017 6:51:22 AM
Amgen (AMGN) And Harvard Pilgrim Agree To First Cardiovascular Outcomes-Based Refund Contract For Repatha (Evolocumab) 5/3/2017 8:11:49 AM
Harvard Pilgrim Signs Second Groundbreaking Contract With Amgen (AMGN) For Repatha 5/3/2017 6:12:15 AM
Why Biotech Giant Amgen (AMGN)'s Q1 Results Indicate the Need for an M&A 4/28/2017 6:16:36 AM
Amgen (AMGN) Reports First Quarter 2017 Financial Results 4/27/2017 9:38:30 AM
Coherus Completes Patent Dance Exchange With Amgen (AMGN) For Neulasta Biosimilar 4/25/2017 9:49:34 AM